NCT04045795: Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04035226 - Study of Real-life Current Standards of Care in Patients With RRMM with 3 prior lines
NCT03989414: Phase 1/2 - A Study of CC-92480 With Standard Treatments in Relapsed & New MM - MM-002
NCT03617731: Phase 3 - Effect of Isatuximab to RVd Induction and Len Maintenance in NDMM (GMMG HD7)
RADAR (UK-MRA Myeloma XV): treatment escalation and de-escalation strategies in NDMM - TE Myeloma
NCT03319667: Phase 3 - Isatuximab, Bortezomib, Lenalidomide and Dexamethasone NDMM (IMROZ)
NCT03104842: Phase 2 - GMMG - CONCEPT - Eval. iNduction, Consol. & Maint. Isatuximab Carf Len. & Dex
NCT03275285: Phase 3 - Isatuximab, Carf & Dex VS Carf And Dex In Relapse Multiple Myeloma (IKEMA)
NCT02960555: Phase 2 - Isatuximab in Patients With High Risk Smoldering Plasma Cell Myeloma
NCT02990338: Phase 3 - Isatuximab, Pomalidomide & Dex VS Pom & Dex in relapsed Myeloma (ICARIA-MM)
NCT02332850: Phase Ib Study of SAR650984 With Carfilzomib for Treatment of Relapsed Multiple Myeloma